Furthermore, Mcl-1 and cFLIP play rate-limiting roles in TrkAIII transfectant-sensitivity to TRAIL-induced apoptosis, suggesting that cFLIP and/or Mcl-1 inhibitors, combined with novel TRAIL and TRAIL-receptor agonist formulations could represent an important tumour-specific immunotherapy option for TrkAIII expressing tumours (Schematized in Fig. 8). This evidence concerns the gene TNFSF10 and neoplasm.